BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei H, Cui C, Cui X, Liu Y, Li D. Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China. BMC Health Serv Res 2021;21:96. [PMID: 33509171 DOI: 10.1186/s12913-021-06084-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Feng T, Zheng Z, Gao S, Xu J, Cao P, Jia H, Yu X. Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease. Front Pharmacol 2022;13:921387. [DOI: 10.3389/fphar.2022.921387] [Reference Citation Analysis]
2 Choi JH, Kim W, Kim YT, Cho J, Shin SY, Kim C, Kim J. Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk. Front Cardiovasc Med 2022;9:849474. [DOI: 10.3389/fcvm.2022.849474] [Reference Citation Analysis]
3 Pyykönen M, Linna M, Tykkyläinen M, Delmelle E, Laatikainen T. Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin. BMC Health Serv Res 2021;21:1299. [PMID: 34856979 DOI: 10.1186/s12913-021-07125-5] [Reference Citation Analysis]
4 Zhou H, Nie X, Jiang M, Dong W. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. J Clin Pharm Ther 2021. [PMID: 34783090 DOI: 10.1111/jcpt.13575] [Reference Citation Analysis]
5 Lu W, Wang Y, Chen L, Li Y, Zhang R, Chen Z, Yan J, Yang M, Han B, Wang Z, He S, Chen L, Wu X, Zeng H, Ma L, Shi G, Yin J, Chen J, Ma G. Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention. Front Cardiovasc Med 2021;8:745549. [PMID: 34712714 DOI: 10.3389/fcvm.2021.745549] [Reference Citation Analysis]